Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 3/20 | 0.51 |
| ▸ | HTR2A | P28223 | 3/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.51 |
| ▸ | HTR1D | P28221 | 2/20 | 0.51 |
| ▸ | HRH1 | P35367 | 2/20 | 0.51 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.51 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.47 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.47 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.47 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MLNR | O43193 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1994505 | 1.00 | HTR1A (0.51) | HTR1AHTR2AKCNH2HTR1DHRH1 | |
| SCHEMBL8566386 | 1.00 | HTR1A (0.51) | HTR1AHTR2AKCNH2HTR1DHRH1 | |
| SCHEMBL4382179 | 0.98 | HTR1A (0.50) | HTR1AHTR2AKCNH2HTR1DHRH1 | |
| SCHEMBL10326683 | 0.98 | HTR1A (0.50) | HTR1AHTR2AKCNH2HTR1DHRH1 | |
| SCHEMBL1232420 | 0.98 | HTR1A (0.50) | HTR1AHTR2AKCNH2HTR1DHRH1 | |
| Hydrochloric Acid SCHEMBL8563154 | 0.98 | HTR1A (0.50) | HTR1AHTR2AKCNH2HTR1DHRH1 | |
| SCHEMBL1997768 | 0.98 | HTR1A (0.50) | HTR1AHTR2AKCNH2HTR1DHRH1 | |
| Hydrochloric Acid SCHEMBL8561237 | 0.96 | HTR1A (0.49) | HTR1AHTR2AKCNH2HTR1DHRH1 | |
| SCHEMBL10264864 | 0.96 | HTR1A (0.51) | HTR1AHTR2AKCNH2HTR1DHRH1 | |
| SCHEMBL16716869 | 0.93 | HTR1A (0.45) | HTR1AHTR2AKCNH2HTR1DHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240180895-A1 | USE OF KAPPA OPIOID RECEPTOR AGONISTS TO TREAT CARDIOVASCULAR DISEASE | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE | 2024-06-06 | — | — | US | disclosed |
| US-20230181569-A1 | COMPOSITIONS AND METHODS TO TREAT POLYCYSTIC KIDNEY DISEASE | UNIV LOUISIANA STATE (US) | 2023-06-15 | — | — | US | disclosed |
| US-9326987-B2 | Indazole derivatives for use in the treatment of influenza virus infection | GLAXO GROUP LIMITED (GB) | 2016-05-03 | — | — | US | disclosed |
| EP-2406255-B1 | 4-OXADIAZOL-2-YL-INDAZOLES AS INHIBITORS OF PI3 KINASES | GLAXO GROUP LTD (GB) | 2015-04-29 | — | — | EP | disclosed |
| US-20130165433-A1 | Novel Use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-06-27 | — | — | US | disclosed |
| US-8217204-B2 | Catalyst for asymmetric hydrogenation | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2012-07-10 | — | — | US | disclosed |
| US-8217204-B2 | Catalyst for asymmetric hydrogenation | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2012-07-10 | — | — | US | disclosed |
| US-8212037-B2 | Process for production of optically active quinuclidinols | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20120149703-A1 | AZA-SUBSTITUTED SPIRO DERIVATIVES | JITSUOKA MAKOTO (JP) | 2012-06-14 | — | — | US | disclosed |
| US-8158791-B2 | Aza-substituted spiro derivatives | MSD K.K. (JP) | 2012-04-17 | — | — | US | disclosed |
| EP-0333427-A1 | Heterocyclic derivatives | Smithkline Beecham Farmaceutici S.p.A. (IT) | 1989-09-20 | — | — | EP | disclosed |
| EP-0333315-A1 | Azacyclic compounds, processes for their preparation and their pharmaceutical use | Dr. Lo. Zambeletti S.p.A. (IT) | 1989-09-20 | — | — | EP | disclosed |
| EP-0330468-A2 | Use of heterocyclic derivatives as kappa-opioid receptor agonists in the treatment of cerebral ischaemia | GLAXO GROUP LIMITED (GB) | 1989-08-30 | — | — | EP | disclosed |
| EP-0156191-B1 | CONDENSED DIAZEPINONES, PROCESS FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THESE COMPOUNDS | Dr. Karl Thomae GmbH (DE) | 1989-07-19 | — | — | EP | disclosed |
| US-4826819-A | Piperidine analgesics | DR. LO ZAMBELETTI S.P.A. (IT) | 1989-05-02 | — | — | US | disclosed |
| US-4801585-A | Cyclic carboxamide derivatives and their use as analgesics | DR.LO.ZAMBELETTI S.P.A. (IT) | 1989-01-31 | — | — | US | disclosed |
| EP-0260041-A1 | 1-Acyl-substituted piperidine derivatives | Dr. Lo. Zambeletti S.p.A. (IT) | 1988-03-16 | — | — | EP | disclosed |
| EP-0232612-A1 | Azacyclic compounds, processes for their preparation, and their use as pharmaceuticals | Dr. Lo. Zambeletti S.p.A. (IT) | 1987-08-19 | — | — | EP | disclosed |
| US-4550107-A | Condensed diazepinones, their compositions and methods of use as pharmaceuticals | DR. KARL THOMAE GMBH (DE) | 1985-10-29 | — | — | US | disclosed |
| EP-0156191-A2 | Condensed diazepinones, process for their preparation and medicaments containing these compounds | Dr. Karl Thomae GmbH (DE) | 1985-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149703-A1 | AZA-SUBSTITUTED SPIRO DERIVATIVES | AZI2, NR3C2, DNMT3A | HTR1A 1821/4885HTR2A 1166/4885KCNH2 416/4885 |
| US-20130165433-A1 | Novel Use | HAVCR2, MAVS, ENTPD5 | HTR1A 2919/4885HTR2A 3304/4885KCNH2 4213/4885 |
| US-20230181569-A1 | COMPOSITIONS AND METHODS TO TREAT POLYCYSTIC KIDNEY DISEASE | OPRK1, OPRL1, AVPR1A | HTR1A 321/4885HTR2A 268/4885KCNH2 419/4885 |
| US-20240180895-A1 | USE OF KAPPA OPIOID RECEPTOR AGONISTS TO TREAT CARDIOVASCULAR DISEASE | OPRK1, OPRL1, OPRM1 | HTR1A 252/4885HTR2A 387/4885KCNH2 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.